Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions

Pharmaceutical Biology

Volumn 52, Issue 7, 2014, Pages 814-828

  Visnagri, Asjad ^a   Kandhare, Amit D ^a   Chakravarty, Shalendra ^a   Ghosh, Pinaki ^a   Bodhankar, Subhash L ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

IL 1 ; Insulin; Nerve conduction velocity; Oxido nitrosative stress; TNF

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDEHYDE REDUCTASE; CALCIUM; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HESPERIDIN; INSULIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT;

ADULT; ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERALGESIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; MONOTHERAPY; MOTOR NERVE CONDUCTION; NEUROPATHIC PAIN; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PAIN THRESHOLD; RAT; SENSORY NERVE CONDUCTION; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; TREATMENT OUTCOME; ANIMAL; BLOOD; CHEMICALLY INDUCED; DIABETIC NEUROPATHIES; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; NERVE CONDUCTION; NEURALGIA; PAIN MEASUREMENT; PHYSIOLOGY; SCIATIC NERVE;

ALDEHYDE REDUCTASE; ANIMALS; BIOLOGICAL MARKERS; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HESPERIDIN; HYPERALGESIA; HYPERGLYCEMIA; INSULIN; INTERLEUKIN-1BETA; NEURAL CONDUCTION; NEURALGIA; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PAIN MEASUREMENT; RATS; SCIATIC NERVE; SODIUM-POTASSIUM-EXCHANGING ATPASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899673615     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2013.870584     Document Type: Article

References (116)

1. Akiyama S, Katsumata S-I, Suzuki K, et al. (2010). Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocininduced marginal type 1 diabetic rats. J Clin Biochem Nutr 46:87-92.
2. Ar'rajab A, Ahrén B. (1993). Long-term diabetogenic effect of streptozotocin in rats. Pancreas 8:50-7.
3. Arai K, Maguchi S, Fujii S, et al. (1987). Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. J Biol Chem 262:16969-72.
4. Baydas G, Sonkaya E, Tuzcu M, et al. (2005). Novel role for gabapentin in neuroprotection of central nervous system in streptozotocineinduced diabetic rats 1. Acta Pharmacol Sin 26:417-22.
5. Bhatt L, Veeranjaneyulu A. (2010). Minocycline with aspirin: A therapeutic approach in the treatment of diabetic neuropathy. Neurolog Sci 31:705-16.
6. Bhattacharya G. (1955). On the protection against alloxan ciabetes by hexoses. Science (New York, NY) 121:427.
7. Bonting S. (1970). Presence of Enzyme System in Mammalian Tissues. Membrane and Ion Transport. London: Wiley Inter Science, 257-63.
8. Brecher P. (1983). The interaction of long-chain acyl CoA with membranes. Mol Cell Biochem 57:3-15.
9. Calcutt N, Freshwater J, Mizisin A. (2004). Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47:718-24.
10. Callaghan MJ, Ceradini DJ, Gurtner GC. (2005). Hyperglycemiainduced reactive oxygen species and impaired endothelial progenitor cell function. Antioxid Redox Signal 7:1476-82.
11. Cameron NE, Cotter MA, Robertson S. (1991). Essential fatty acid diet supplementation. Effects on peripheral nerve and skeletal muscle function and capillarization in streptozocin-induced diabetic rats. Diabetes 40:532-9.
12. Chaplan S, Bach F, Pogrel J, et al. (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Meth 53:55-63.
13. Cook N, Samman S. (1996). Flavonoids-Chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 7:66-76.
14. Coppey LJ, Gellett JS, Davidson EP, et al. (2001). Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br J Pharmacol 134:21-9.
15. Courteix C, Eschalier A, Lavarenne J. (1993). Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 53:81-8.
16. Davidson JA. (2004). Treatment of the patient with diabetes: Importance of maintaining target HbA1c levels. Curr Med Res Opin 20:1919-27.
17. Dinarello CA. (2009). Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 27:519-50.
18. Ditzel J, Dyerberg J. (1977). Hyperlipoproteinemia, diabetes, and oxygen affinity of hemoglobin. Metabolism 26:141-50.
19. Dobretsov M, Romanovsky D, Stimers JR. (2007). Early diabetic neuropathy: Triggers and mechanisms. World J Gastroenterol (WJG) 13:175-91.
20. Dyck PJ, Zimmerman BR, Vilen TH, et al. (1988). Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. New Engl J Med 319:542-8.
21. Emim JA, Oliveira AB, Lapa AJ. (1994). Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice. J Pharm Pharmacol 46:118-22.
22. Friedmann N, Gellhorn A, Benjamin W. (1966). Synthesis of arachidonic acid from linoleic acid in vivo in diabetic rats. Israel J Med Sci 2: 677-82.
23. Gabay C, Lamacchia C, Palmer G. (2010). IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232-41.
24. Garner MH, Spector A. (1987). Direct stimulation of Na+-K+-ATPase and its glucosylated derivative by aldose reductase inhibitor. Diabetes 36:716-20.
25. Ghosh P, Kandhare AD, Raygude KS, et al. (2012). Determination of the long term diabetes related complications and cardiovascular events using UKPDS risk engine and UKPDS outcomes model in a representative western Indian population. Asian Pac J Trop Dis 2: S642-S50.
26. Gidal B, Billington R. (2006). New and emerging treatment options for neuropathic pain. Am J Manag Care 12:S269-78.
27. Gosavi T, Ghosh P, Kandhare A, Bodhankar S. (2011). Unwrapping homeopathic principles in the wake of research: Serendipity, placebo or true therapeutic milestones. Pharmacologyonline 1:894-906.
28. Gosavi TP, Kandhare AD, Ghosh P, Bodhankar SL. (2012). Anticonvulsant activity of Argentum metallicum, a homeopathic preparation. Der Pharmacia Lett 4:626-37.
29. Goto Y, Hotta N, Shigeta Y, et al. (1995). Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 49: 269-77.
30. Greene DA, Sima AA, Stevens MJ, et al. (1992). Complications: Neuropathy, pathogenetic considerations. Diabetes Care 15:1902-25.
31. Group DR. (1994). Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes control and complications trial. J Pediatr 125:177-88.
32. Guneli E, Kazikdas KC, Kolatan E. (2007). Ghrelin may attenuate proinflammatory cytokine-mediated neuropathic pain. Med Hypotheses 69:356-60.
33. Gustafson-Vickers SL, Lu VB, Lai AY, et al. (2008). Long-term actions of interleukin-1beta on delay and tonic firing neurons in rat superficial dorsal horn and their relevance to central sensitization. Mol Pain 4: 63-73.
34. Halliwell B. (1991). Drug antioxidant effects. A basis for drug selection? Drugs 42:569-605.
35. Hargreaves K, Dubner R, Brown F, et al. (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32:77-88.
36. Head KA. (2006). Peripheral neuropathy: Pathogenic mechanisms and alternative therapies. Alternat Med Rev 11:294-329.
37. Hirata Y, Okada K. (1990). Relation of Na+, K(+)-ATPase to delayed motor nerve conduction velocity: Effect of aldose reductase inhibitor, ADN-138, on Na+, K(+)-ATPase activity. Metabolism 39:563-7.
38. Huang H-Y, Appel LJ. (2003). Supplementation of diets with a-tocopherol reduces serum concentrations of g-and d-tocopherol in humans. J Nutr 133:3137-40.
39. Ibrahim SS. (2008). Protective effect of hesperidin, a citrus bioflavonoid, on diabetes-induced brain damage in rats. J Appl Sci Res 4:84-95.
40. Jean T, Bodinier M. (1994). Mediators involved in inflammation: Effects of Daflon 500 mg on their release. Angiology 45:554-9.
41. Jensen TS, Baron R. (2003). Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 102:1-8.
42. Jin YR, Han XH, Zhang YH, et al. (2008). Hesperetin, a bioflavonoid, inhibits rat aortic vascular smooth muscle cells proliferation by arresting cell cycle. J Cell Biochem 104:1-14.
43. Jung UJ, Lee M-K, Jeong K-S, Choi M-S. (2004). The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr 134: 2499-503.
44. Kandhare A, Raygude K, Ghosh P, Bodhankar S. (2011a). The ameliorative effect of fisetin, a bioflavonoid, on ethanol-induced and pylorus ligation-induced gastric ulcer in rats. Int J Green Pharmacy 5:236-43.
45. Kandhare AD, Raygude KS, Ghosh P, et al. (2011b). Patentability of animal models: India and the globe. Intl J PharmBiol Arch 2:1024-32.
46. Kandhare AD, Kumar VS, Adil M, et al. (2012a). Investigation of gastro protective activity of Xanthium strumarium L. by modulation of cellular and biochemical marker. Orient Pharm Exp Med 12:287-99.
47. Kandhare AD, Raygude KS, Ghosh P, et al. (2012b). Neuroprotective effect of naringin by modulation of endogenous biomarkers in streptozotocin induced painful diabetic neuropathy. Fitoterapia 83: 650-9.
48. Kandhare AD, Raygude KS, Ghosh P, et al. (2012c). Therapeutic role of curcumin in prevention of biochemical and behavioral aberration induced by alcoholic neuropathy in laboratory animals. Neurosci Lett 511:18-22.
49. Kandhare AD, Raygude KS, Ghosh P, et al. (2012d). Effect of hydroalcoholic extract of Hibiscus rosa sinensis Linn. leaves in experimental colitis in rats. Asian Pac J Trop Biomed 5:337-44.
50. Kandhare AD, Raygude KS, Shiva Kumar V, et al. (2012e). Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats. Biomed Aging Pathol 2:173-86.
51. Kandhare AD, Ghosh P, Ghule AE, Bodhankar SL. (2013a). Elucidation of molecular mechanism involved in neuroprotective effect of Coenzyme Q10 in alcohol induced neuropathic pain. Fundam Clin Pharmacol 27:603-22.
52. Kandhare AD, Ghosh P, Ghule AE, et al. (2013b). Protective effect of Phyllanthus amarus by modulation of endogenous biomarkers and DNA damage in acetic acid induced ulcerative colitis: Role of phyllanthin and hypophyllanthin. Apollo Med 10:87-97.
53. Kapur D. (2003). Neuropathic pain and diabetes. Diabetes/Metab Res Rev 19:S9-15.
54. Kaur G, Tirkey N, Chopra K. (2006). Beneficial effect of hesperidin on lipopolysaccharide-induced hepatotoxicity. Toxicology 226:152-60.
55. Kawaguchi K, Mizuno T, Aida K, Uchino K. (1997). Hesperidin as an inhibitor of lipases from porcine pancreas and Pseudomonas. Biosci Biotechnol Biochem 61:102-4.
56. Kim SY, Lee JH, Yang ES, et al. (2003). Human sensitive to apoptosis gene protein inhibits peroxynitrite-induced DNA damage. Biochem Biophys Res Commun 301:671-4.
57. Kishi Y, Nickander KK, Schmelzer JD, Low PA. (2000). Gene expression of antioxidant enzymes in experimental diabetic neuropathy. J Peripher Nerv Syst 5:11-18.
58. Kuhad A, Chopra K. (2009). Tocotrienol attenuates oxidative-nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy. Neuropharmacology 57:456-62.
59. Kumar A, Kaundal RK, Iyer S, Sharma SS. (2007). Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci 80:1236-44.
60. Lee N-K, Choi S-H, Park S-H, et al. (2004). Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology 71: 174-80.
61. Lonchampt M, Guardiola B, Sicot N, et al. (1989). Protective effect of a purified flavonoid fraction against reactive oxygen radicals. In vivo and in vitro study. Arzneimittel-Forschung 39:882-5.
62. Low PA, Nickander KK. (1991). Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873-7.
63. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-75.
64. Matkovics B, Kotorman M, Varga IS, et al. (1997). Oxidative stress in experimental diabetes induced by streptozotocin. Acta Physiol Hungarica 85:29-38.
65. Matrisian LM. (2005). The matrix-degrading metalloproteinases. Bioassays 14:455-63.
66. Milenkovic D, Deval C, Dubray C, et al. (2011). Hesperidin displays relevant role in the nutrigenomic effect of orange juice on blood leukocytes in human volunteers: A randomized controlled cross-over study. PloS One 6:e26669.
67. Miranda KM, Espey MG, Wink DA. (2001). A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide: Biol Chem/Official J Nitric Oxide Soc 5:62-71.
68. Misra HP, Fridovich I. (1972). The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247:3170-5.
69. Moron MS, Depierre JW, Mannervik B. (1979). Levels of glutathione, glutathione reductase and glutathione-S-transferase activities in rat lung and liver. Biochim Biophys Acta (BBA)-Gen Subj 582:67-78.
70. Nagamatsu M, Nickander KK, Schmelzer JD, et al. (1995). Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18:1160-7.
71. Nandakumar N, Jayaprakash R, Rengarajan T, et al. (2011). Hesperidin, a natural citrus flavonoglycoside, normalizes lipid peroxidation and membrane bound marker enzymes in 7, 12-dimethylbenz (a) anthracene induced experimental breast cancer rats. Biomed Prev Nutr 1: 255-62.
72. Necker R, Hellon R. (1978). Noxious thermal input from the rat tail: Modulation by descending inhibitory influences. Pain 4:231-42.
73. Newby AC. (2005). Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85: 1-31.
74. Niedowicz DM, Daleke DL. (2005). The role of oxidative stress in diabetic complications. Cell Biochem Biophys 43:289-330.
75. Nishikawa T, Edelstein D, Du XL, et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-90.
76. Obrosova IG, Drel VR, Pacher P, et al. (2005). Oxidative-nitrosative stress and poly (ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy the telation is revisited. Diabetes 54:3435-41.
77. Opara E. (2002). Oxidative stress, micronutrients, diabetes mellitus and its complications. J R Soc Promot Health 122:28-34.
78. Pabbidi RM, Yu S-Q, Peng S, et al. (2008). Influence of TRPV1 on diabetes-induced alterations in thermal pain sensitivity. Mol Pain 4:9.
79. Patil M, Kandhare A, Bhise S. (2012a). Anti-inflammatory effect of Daucus carota root on experimental colitis in rats. Int J Pharm Pharm Sci 4:337-43.
80. Patil MVK, Kandhare AD, Bhise SD. (2012b). Anti-arthritic and antiinflammatory activity of Xanthium strumarium L. ethanolic extract in Freund's complete adjuvant induced arthritis. Biomed Aging Pathol 2: 6-15.
81. Patil MVK, Kandhare AD, Bhise SD. (2012c). Effect of aqueous extract of Cucumis sativus Linn. fruit in ulcerative colitis in laboratory animals. Asian Pac J Trop Biomed 2:S962-9.
82. Patil MVK, Kandhare AD, Ghosh P, Bhise SD. (2012d). Determination of role of GABA and nitric oxide in anticonvulsant activity of Fragaria vesca L. ethanolic extract in chemically induced epilepsy in laboratory animals. Oriental Pharm Exp Med 12:255-64.
83. Perkins N, Tracey D. (2000). Hyperalgesia due to nerve injury: Role of neutrophils. Neuroscience 101:745-57.
84. Pires Das Neves RN, Carvalho F, Carvalho M, et al. (2004). Protective activity of hesperidin and lipoic acid against sodium arsenite acute toxicity in mice. Toxicol Pathol 32:527-35.
85. Quattrini C, Tesfaye S. (2003). Understanding the impact of painful diabetic neuropathy. Diabetes/Metab Res Rev 19:S2-8.
86. Randall LO, Selitto JJ. (1957). A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111:409-19.
87. Raygude KS, Kandhare AD, Ghosh P, Bodhankar SL. (2012a). Anticonvulsant effect of fisetin by modulation of endogenous biomarkers. Biomed Prev Nutr 2:215-22.
88. Raygude KS, Kandhare AD, Ghosh P, et al. (2012b). Evaluation of ameliorative effect of quercetin in experimental model of alcoholic neuropathy in rats. Inflammopharmacology 20:331-41.
89. Rice-Evans C, Miller N, Paganga G. (1997). Antioxidant properties of phenolic compounds. Trends Plant Sci 2:152-9.
90. Rizza S, Muniyappa R, Iantorno M, et al. (2011). Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 96:E782-92.
91. Rossetti L, Giaccari A, Defronzo RA. (1990). Glucose toxicity. Diabetes Care 13:610-30.
92. Said G. (2007). Diabetic neuropathy-A review. Nat Clin Pract Neurol 3:331-40.
93. Samad TA, Moore KA, Sapirstein A, et al. (2001). Interleukin-1bmediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410:471-5.
94. Sayyed SG, Kumar A, Sharma SS. (2006). Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy. Life Sci 79:777-83.
95. Scholz J, Woolf CJ. (2007). The neuropathic pain triad: Neurons, immune cells and glia. Nat Neurosci 10:1361-8.
96. Serpell M. (2006). Anatomy, physiology and pharmacology of pain. Surgery (Oxford) 24:350-3.
97. Severenghaus J, Ferrebee J. (1950). Calcium determination by flame photometry; methods for serum, urine, and other fluids. J Biol Chem 187:621-30.
98. Shah JK, Patel N. (2010). Effect of hesperidin on renal complication in experimentally induced renal damage in diabetic Sprague-Dawley rats. J Ecobiotechnol 2:35-40.
99. Sharma A, Thomas P, De Molina A. (1977). Peripheral nerve fiber size in experimental diabetes. Diabetes 26:689-92.
100. Shi X, Liao S, Mi H, et al. (2012). Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Molecules 17:12868-81.
101. Sima A. (2006). Pathological mechanisms involved in diabetic neuropathy: Can we slow the process? Curr Opin Invest Drugs 7:324-37
102. Slater T, Sawyer B. (1971). The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. General features of the systems used. Biochem J 123:805-14.
103. Soriano FG, Pacher P, Mabley J, et al. (2001). Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly (ADP-ribose) polymerase. Circ Res 89:684-91.
104. Sorkin LS, Doom CM. (2001). Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst 5:96-100.
105. Stevens MJ, Obrosova I, Cao X, et al. (2000). Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 49: 1006-15.
106. Sudoh Y, Desai SP, Haderer AE, et al. (2004). Neurologic and histopathologic evaluation after high-volume intrathecal amitriptyline. Reg Anesth Pain Med 29:434-40.
107. Valensi P, Le Devehat C, Richard J-L, et al. (2005). A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy: A preliminary report. J Diabetes Compl 19:247-53.
108. Verri Jr W, Cunha TM, Parada CA, et al. (2006). Hypernociceptive role of cytokines and chemokines: Targets for analgesic drug development? Pharmacol Therapeut 112:116-38
109. Vincent AM, Russell JW, Low P, Feldman EL. (2004). Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrine Rev 25:612-28.
110. Visnagri A, Kandhare AD, Shiva Kumar V, et al. (2012). Elucidation of ameliorative effect of co-enzyme Q10 in streptozotocin-induced diabetic neuropathic perturbation by modulation of electrophysiological, biochemical and behavioral markers. Biomed Aging Pathol 2: 157-72.
111. Wild S, Roglic G, Green A, et al. (2004). Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-53.
112. Wuarin-Bierman L, Zahnd G, Kaufmann F, et al. (1987). Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia 30:653-8.
113. Yoon SL, Horne CH, Adams C. (2004). Herbal product use by African American older women. Clin Nurs Res 13:271-88.
114. Yurchenco PD, Schittny JC. (1990). Molecular architecture of basement membranes. FASEB J 4:1577-90.
115. Ziegler D, Hanefeld M, Ruhnau KJ, et al. (1999). Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III study group. Alpha-lipoic acid in diabetic neuropathy. Diabetes Care 22:1296-301.
116. Zochodne D, Levy D. (2005). Nitric oxide in damage, disease and repair of the peripheral nervous system. Cell Mol Biol (Noisy-le-Grand, France) 51:255-67.